Slide 1: Thyrocare - Think Thyroid. Think Thyrocare.
Thyrocare· Think Thyroid. Think Thyrocare. February O 1, 2021 I To, National Stock Exchange of India Limited SSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Sandra Kurla Complex, Dalal Street, Sandra (E), Mumbai - 400 051 Mumbai- 400 00 I Dear Sirs, Sub: Presentation on Quarterly Results for the
Slide 2: Disclaimer
Thyrocare Technologies Limited Presentation – Q32021 Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements o
Slide 3: Key Highlights
Key Highlights Revenue from Standalone Quarterly revenue increased by 35% YoY operations Consolidated Quarterly revenue increased by 31% YoY • Q3 Pathology Revenue of Rs. 132.17 Crore, consists of Covid RTPCR Revenue of Rs. 27.34 Crore. • Pathology Revenue (excluding Covid RTPCR) revived fully in Q3
Slide 4: Financial Performance - Thyrocare
Financial Performance - Thyrocare Thyrocare Technologies Limited Statement of Unaudited Standalone Financial Results (Rs. in crore, except per share data) Particulars Quarter ended YTD 31.12.2020 % 30.09.2020 % 31.12.2019 % 31.12.2020 % 31.12.2019 % Revenue from operations 132.17 148.54 97.99 335.12
Slide 5: Operational Performance - Thyrocare
Operational Performance - Thyrocare
Slide 6: Financial Performance - Nueclear
Financial Performance - Nueclear Nueclear Healthcare Limited Statement of Unaudited Standalone Financial Results (Rs. in crore, except per share data) Particulars Quarter ended YTD 31.12.2020 % 30.09.2020 % 31.12.2019 % 31.12.2020 % 31.12.2019 % Revenue from operations 6.16 4.71 7.91 12.73 25.99 Cos
Slide 7: Operational Performance - Nueclear
Operational Performance - Nueclear Centre Revenue Q1 Q2 Q3 Navi Mumbai 0.35 0.67 0.95 Delhi 0.02 0.37 0.76 Hyderabad 0.03 0.66 0.92 Prabhadevi 0.46 0.70 0.95 Aurangabad 0.26 0.42 0.46 Jaipur 0.23 0.62 0.60 Nashik 0.42 0.52 0.73 Bangalore 0.00 0.04 0.30 Total 1.77 4.01 5.66 Centre Scans Q1 Q2 Q3 Navi
Slide 8: Consolidated Financial Performance - Thyrocare
Consolidated Financial Performance - Thyrocare Thyrocare Technologies Limited [Consolidated] Statement of Unaudited Consolidated Financial Results (Rs. in crore, except per share data) Particulars Quarter ended YTD 31.12.2020 % 30.09.2020 % 31.12.2019 % 31.12.2020 % 31.12.2019 % Revenue from operati
Slide 9: YTD Updates
YTD Performance - Thyrocare YTD Updates Total Revenue from pathology business (including Covid RTPCR) – Rs. 334.19 Crore (Previous Year – Rs. 304.21 Crore). Total Revenue from Covid RTPCR – Rs. 98.34 Crore (29% of Total revenue from pathology business) Total non covid samples processed and rep
Slide 10: Business update
Business update Preventive care Business – constitutes significant proportion of our topline which has seen set back during pandemic. We are seeing significant revival of the preventive care business in the current quarter. The contribution of revenue from sale of Aarogyam profiles/ packages in the
Slide 11: Thank You
Thyrocare’ The Trust. The Truth. THANK YOU